Fetal proteins in various tumors

Area of Science:

• Oncology
• Hematology
• Biochemistry

Background:

• Fetal hemoglobin (HbF) is typically present at high levels in newborns, decreasing to low levels after birth.
• Elevated HbF can sometimes be associated with certain hematological conditions and malignancies.
• Alpha-fetoprotein (AFP) is a tumor marker often elevated in liver cancer and other malignancies.

Purpose of the Study:

• To investigate the prevalence of elevated fetal hemoglobin (HbF) concentrations in patients diagnosed with various types of cancer.
• To explore the correlation between HbF levels, total hemoglobin, and serum alpha-fetoprotein (AFP) concentrations in cancer patients.

Main Methods:

• Radial immunodiffusion assay was employed to quantify HbF levels in 312 cancer patients.
• Radioimmunoassay was utilized to measure serum AFP concentrations in 305 of these patients.
• Statistical analysis was performed to identify correlations between HbF, total hemoglobin, and AFP.

Main Results:

• Increased HbF concentrations (exceeding 3 standard deviations above the normal mean) were detected in 68 out of 312 patients (approximately 21.8%).
• Notably higher HbF levels were observed in patients with leukemia, multiple myeloma, lymphoma, bladder carcinoma, and testicular tumors.
• A significant correlation was found between HbF and serum AFP concentrations in patients with hepatoma and bladder carcinoma.

Conclusions:

• Elevated HbF is a notable finding in a subset of patients with diverse malignancies, particularly hematological cancers and certain carcinomas.
• The correlation between HbF and AFP in specific cancers suggests potential shared regulatory pathways or biological roles in tumorigenesis.
• Further research is warranted to elucidate the clinical significance and underlying mechanisms of elevated HbF in cancer.